<?xml version="1.0" encoding="UTF-8"?>
<p id="p0255">Kai Duan etÂ al. showed that administration of convalescent plasma (CP) obtained from recovered COVID-19 patients who had established humoral immunity against the virus led to COVID-19 patients achieving serum SARS-CoV-2 RNA negativity after CP transfusion, accompanied by an increase of oxygen saturation and lymphocyte counts, and the improvement of liver function and CRP. Key factors in administering convalescent plasma include concerns that donor plasma must contain an adequate titre of neutralizing antibodies, be administered at the right treatment time point and risk of transmitting potential pathogens must be considered. Mass testing of recovered patients who meet above criteria can provide an efficacious treatment source for COVID- 19 patients [
 <xref rid="bib37" ref-type="bibr">37</xref>].
</p>
